Enesi Pharma is an early stage pharmaceutical company developing innovative products with potential to transform performance and delivery of vaccines and make a material impact on global healthcare.
The company’s primary focus is the development of novel solid dose vaccines against a range of infectious and other select diseases, working in partnership with global companies, government agencies and non-governmental organisations.
Enesi’s ImplaVax® formulation and device technologies offer significant potential benefits for patients, care givers, healthcare professionals and payers through enhanced effectiveness, safety, ease of use, reliability and stability, and are supported by a strong patient preference over a standard needle and syringe.
Enesi’s experienced leadership team has a proven track record in the successful development and commercialisation of innovative products delivering high value outcomes for all stakeholders. Follow Enesi on Twitter at www.twitter.com/enesi_pharma